A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 16-Week Trial to Evaluate the Efficacy and Safety of FB-401 in Children, Adolescents, and Adult Subjects (Ages 2 Years and Older) with Mild-to-Moderate Atopic Dermatitis
Dermatology · 2024 · 240 (1) · 85-94
DOI: 10.1159/000532054 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Dermatology, online erschienen am 14.08.2023. Verfasst von Michael E Jacobson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Oregon Health and Science University, Portland, Oregon, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Atopic dermatitis is a common chronic, relapsing, and remitting inflammatory skin disorder associated with cutaneous dysbiosis. Current treatment options often fail to adequately control the disease and have unfavorable safety profiles. There is a need for new options that address these treatment shortcomings.
Objective
The aim of the study was to evaluate the efficacy, safety, and tolerability of FB-401, a live therapeutic product of 3 strains of Roseomonas mucosa, compared to matching placebo applied topically 3 times per week to participants ages ≥2 years of age with mild-to-moderate atopic dermatitis.
Methods
A randomized, double-blind, placebo-controlled, parallel-group study was conducted. The primary outcome was the proportion of participants with 50% improvement in Eczema Area and Severity Index score from baseline at week 16. 154 subjects aged 2 or older with a clinical diagnosis of atopic dermatitis as defined by Hanifin and Rajka criteria with mild or moderate severity were randomized 1:1 via interactive web response system to FB-401 or placebo.
Results
The proportion of subjects who achieved the primary outcome was similar between both treatment groups, with no significant treatment group differences observed at any post-baseline visit. The number of treatment-emergent adverse events and the number of subjects with at least one were similar across treatment groups. One serious adverse event not related to treatment was reported. No treatment-emergent adverse events led to treatment discontinuation or study discontinuation.
Conclusions
FB-401 showed an acceptable safety profile but failed to prove superior to placebo in treating children and adults with mild-to-moderate atopic dermatitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Oregon Health and Science University, Portland, Oregon, USA.
- Epithelial Therapeutics Unit, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.
- Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
- Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
- Departments of Dermatology and Pediatrics, University of California San Diego, San Diego, California, USA.
- Division of Pediatric and Adolescent Dermatology, Rady Children's Hospital, San Diego, California, USA.
Förderung
- Intramural NIH HHS
Zitieren
APA
Jacobson, M. E., Myles, I. A., Paller, A. S., Eichenfield, L. F., & Simpson, E. L. (2024). A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 16-Week Trial to Evaluate the Efficacy and Safety of FB-401 in Children, Adolescents, and Adult Subjects (Ages 2 Years and Older) with Mild-to-Moderate Atopic Dermatitis. Dermatology, 240(1), 85-94. https://doi.org/10.1159/000532054
Vancouver
Jacobson ME, Myles IA, Paller AS, Eichenfield LF, Simpson EL. A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 16-Week Trial to Evaluate the Efficacy and Safety of FB-401 in Children, Adolescents, and Adult Subjects (Ages 2 Years and Older) with Mild-to-Moderate Atopic Dermatitis. Dermatology. 2024;240(1):85-94. doi:10.1159/000532054
BibTeX
@article{Jacobson2024,
author = {Jacobson, Michael E and Myles, Ian A and Paller, Amy S and Eichenfield, Lawrence F and Simpson, Eric L},
title = {A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 16-Week Trial to Evaluate the Efficacy and Safety of FB-401 in Children, Adolescents, and Adult Subjects (Ages 2 Years and Older) with Mild-to-Moderate Atopic Dermatitis},
journal = {Dermatology},
year = {2024},
volume = {240},
number = {1},
pages = {85--94},
doi = {10.1159/000532054}
}
EUVIMED